Abstract
Aim: To compare treatment results with use of nab-paclitaxel in routine clinical practice with data obtained from clinical trials. Patients and Methods: A retrospective chart review of all 36 patients with metastatic breast cancer treated with nab-paclitaxel was performed. Nab-paclitaxel was given weekly and usually started at 150 mg/m2. Results: Thirteen (36.1%) patients received nab-paclitaxel as first-line, seven (19.4%) as second-line and 16 as third- or further line treatment. Overall, the response rate was 9.7%, disease control rate 64.5%, median progression-free survival 7.5 months and median overall survival 14.2 months. The most frequent non-hematological toxicities of grade 3 or more were fatigue (27.8%), dyspnea, rash and arthalgia (all 5.6%). Six (16.7%) patients developed peripheral neuropathy of grade 2 or more. Incidence of neutropenia grade 3 or more was 41.7% with no case of febrile neutropenia. Conclusion: According to our experience, weekly nab-paclitaxel is effective and tolerable, with results at least comparable to those from the prospective clinical trials.
Footnotes
-
Disclosure
This study was supported by Celgene Corporation, Summit, NJ, USA. The Authors received editorial support in the preparation of this manuscript from Dr. Susanne Hell, funded by Celgene Corporation. The Authors were fully responsible for all content and editorial decisions for this manuscript.
- Received May 7, 2013.
- Revision received May 23, 2013.
- Accepted May 27, 2013.
- Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved